Differential Actions of Dopamine Agonists and Antagonists on the Gamma-butyrolactone-induced in Mouse Brain Dopamine

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1976 Nov 24

PMID 826966

Citations 13

Authors

G Gianutsos

J E Thornburg

K E Moore

Affiliations

Soon will be listed here.

Abstract

gamma-Butyrolactone (GBL) increased the dopamine concentration in the forebrain of the mouse. Apomorphine dose-dependently antagonized the GBL effect, while piribedil was less effective. Haloperidol prevented the antagonism of GBL by apomorphine but pimozide was ineffective in blocking apomorphine. After chronic treatment with haloperidol or pimozide, there was no alteration of the maximum GBL-induced increase in dopamine nor was there any significant change in the antagonism by apomorphine, although a trend toward increased sensitivity to apomorphine was noted in the group withdrawn from haloperidol. These results suggest that in the mouse, haloperidol is a more effective antagonist of presynaptic dopamine autoreceptors than pimozide, while apomorphine is a better presynaptic agonist than piribedil.

Citing Articles

Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.

Bannon M, Bunney E, Zigun J, Skirboll L, Roth R Naunyn Schmiedebergs Arch Pharmacol. 1980; 312(2):161-5.

PMID: 6772975 DOI: 10.1007/BF00569725.

Effects of gamma-butyrolactone, amphetamine, and haloperidol in mice differing in sensitivity to alcohol.

Dudek B, Fanelli R Psychopharmacology (Berl). 1980; 68(1):89-97.

PMID: 6771802 DOI: 10.1007/BF00426656.

Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively.

ANDEN N, Thornstrom U Naunyn Schmiedebergs Arch Pharmacol. 1982; 321(2):100-4.

PMID: 6296699 DOI: 10.1007/BF00518475.

Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide.

Post R, Jimerson D, Bunney Jr W, Goodwin F Psychopharmacology (Berl). 1980; 67(3):297-305.

PMID: 6155678 DOI: 10.1007/BF00431272.

Role of dopamine storage function in the control of rat striatal tyrosine hydroxylase activity.

McMILLEN B, Shore P Naunyn Schmiedebergs Arch Pharmacol. 1980; 313(1):39-44.

PMID: 6111026 DOI: 10.1007/BF00505803.

References

Thornburg J, Moore K . Supersensitivity to dopaminergic agonists induced by haloperidol. Natl Inst Drug Abuse Res Monogr Ser. 1975; (3):23-8. DOI: 10.1037/e475222004-001. View

CORRODI H, Farnebo L, Fuxe K, Hamberger B, Ungerstedt U . ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors. Eur J Pharmacol. 1972; 20(2):195-204. DOI: 10.1016/0014-2999(72)90149-5. View

Chang C . A SENSITIVE METHOD FOR SPECTROPHOTOFLUOROMETRIC ASSAY OF CATECHOLAMINES. Int J Neuropharmacol. 1964; 3:643-9. DOI: 10.1016/0028-3908(64)90089-9. View

Spano P, Tagliamonte A, Tagliamonte P, Gessa G . Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate. J Neurochem. 1971; 18(10):1831-6. DOI: 10.1111/j.1471-4159.1971.tb09588.x. View

Thornburg J, Moore K . A comparison of effects of apomorphine and ET495 on locomotor activity and circling behaviour in mice. Neuropharmacology. 1974; 13(3):189-97. DOI: 10.1016/0028-3908(74)90106-3. View

Gianutsos G, Drawbaugh R, Hynes M, Lal H . Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci. 1974; 14(5):887-98. DOI: 10.1016/0024-3205(74)90078-2. View

Walters J, Roth R, Aghajanian G . Dopaminergic neurons: similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway. J Pharmacol Exp Ther. 1973; 186(3):630-9. View

Walters J, Roth R . Effect of gamma-hydroxybutyrate on dopamine and dopamine metabolites in the rat striatum. Biochem Pharmacol. 1972; 21(15):2111-21. DOI: 10.1016/0006-2952(72)90164-5. View

Walters J, Roth R . Dopaminergic neurons: drug-induced antagonism of the increase in tyrosine hydroxylase activity produced by cessation of impulse flow. J Pharmacol Exp Ther. 1974; 191(1):82-91. View

10.

Tarsy D, Baldessarini R . Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology. 1974; 13(10-11):927-40. DOI: 10.1016/0028-3908(74)90084-7. View

11.

KEHR W, Carlsson A, Lindqvist M, Magnusson T, Atack C . Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol. 1972; 24(9):744-7. DOI: 10.1111/j.2042-7158.1972.tb09104.x. View

12.

VonVoigtlander P, Losey E, Triezenberg H . Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J Pharmacol Exp Ther. 1975; 193(1):88-94. View

13.

Handforth A, Sourkes T . Inhibition by dopamine agonists of dopamine accumulation following gamma-hydroxybutyrate treatment. Eur J Pharmacol. 1975; 34(2):311-9. DOI: 10.1016/0014-2999(75)90257-5. View

14.

ANDEN N, Butcher S, CORRODI H, Fuxe K, Ungerstedt U . Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol. 1970; 11(3):303-14. DOI: 10.1016/0014-2999(70)90006-3. View